Financial Data and Key Metrics Changes - The company reported no financings completed in Q2 2025, leading to limited revenue generation, primarily from Pat Invest [5] - Cash utilization for the first six months of 2025 was $3.4 million, with expectations to close financings in February 2025 to reduce or eliminate cash usage [7] Business Line Data and Key Metrics Changes - The company is focusing on incubating more companies to offset operating expenses with financings, aiming for a balance between equity generation and fee income [6] - The current revenue from launching more developed companies is intended to offset cash operations [6] Market Data and Key Metrics Changes - The company noted a significant investor hesitation towards deep tech life science investments, which has been a challenging segment in the market [9][10] - There is a growing interest in profitable, early-stage companies with revenue momentum, which are highly valued in the current market [13] Company Strategy and Development Direction - The company is expanding its product mix to include profitable companies with revenue momentum, aiming to attract a broader range of investors [14] - A new prospectus was filed for a profitable company in the beverage space, indicating a shift towards diverse investment opportunities beyond life sciences [15][16] - The company is focusing on metabolic health as a significant opportunity, particularly with the rise of GLP-1 drugs, which represent a massive market potential [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the public venture model, highlighting a shift away from private equity and traditional venture capital [17][18] - The company is preparing to spin off PatentVest as an independent public company, which is expected to create additional value for shareholders [50][51] Other Important Information - The company is actively engaging with family offices and RIAs to expand its investor community and explore new investment models [26][30] - A partnership with Koretsu, one of the largest angel groups, was announced to help syndicate investments in public ventures [31][34] Q&A Session Summary Question: Are there vulture opportunities in your core life science market? - Management acknowledged that tough markets often present better opportunities, noting that current valuations are reasonable and there are asymmetric upsides available in life sciences [65][66][67] Question: What's the plan to increase volume and liquidity for portfolio companies? - Management emphasized the importance of having a correct narrative and focusing on near-term inflection points to attract investor interest and increase volume [71][72][73] Question: What is the plan for the holding company's assets and potential distributions? - Management indicated a desire to distribute equity as much as possible, with plans to spin out PatentVest and potentially distribute shares of ExoZyme when market conditions are favorable [83][84][86]

Financial Data and Key Metrics Changes - The company reported a modest increase in its shareholder base, onboarding several new accounts interested in the HeartBeam offering [30] - Net current assets decreased by approximately $2.3 million, with less than $2 million in cash utilized during the quarter [36][37] - The enterprise value calculation indicates that the company was trading at a significant discount to its enterprise value at year-end, which has slightly decreased due to volatility in HeartBeam and Exozymes [34][35] Business Line Data and Key Metrics Changes - The company is pivoting towards companies that are closer to product revenue and value creation, indicating a shift in focus from traditional deep tech ideas [19][50] - The company has three new Letters of Intent (LOIs) with a biotech firm, a profitable beverage company, and a healthcare software company, all of which are expected to perform well in the public markets [20][21][23] Market Data and Key Metrics Changes - The venture market is experiencing a significant backlog of companies that could potentially go public, with many venture firms seeking to exit investments due to a lack of new fund formations [12][15] - The current environment is seen as favorable for small IPOs, with a growing number of companies that could be well-valued in public markets [18][51] Company Strategy and Development Direction - The company aims to curate public venture capital as a preferred alternative to traditional venture capital, focusing on transforming big ideas into valuable public companies [5][6] - The management is excited about the potential for IPOs, believing that the current market dynamics will allow for better valuations and opportunities for public investors [15][16] - The company is expanding its investor community, focusing on capital allocators rather than just deal buyers, to enhance its deal flow [50][45] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenging operating environment but remains optimistic about the potential for future growth and the ability to bring new companies public [24][51] - The management believes that the current market conditions will lead to a resurgence in small IPOs, reversing long-term downtrends [18][51] - The company is committed to finding extraordinary businesses at the right valuations, which will represent great return opportunities for investors [20][52] Other Important Information - The company has restructured its executive compensation plan to align better with shareholder interests, converting a significant amount of stock into options [32][33] - PatentVest is seen as a critical component of the company's strategy, providing essential business development and IP strategy support to portfolio companies [69][70] Q&A Session Summary Question: Can you just talk about the one company that you have that you're financing, the 20,000,000 for the potential cure for diabetes? - The company being financed is PaulX Bio [54] Question: How does management interpret the persistent discount of the MDBH stock price relative to the IPO price? - Management attributes the discount to supply and demand dynamics, noting that market perceptions can change over time [56][59] Question: What is the future dividend policy of the company? - The dividend policy will depend on the impact of share distribution on the companies involved and the company's cash flows [60][62] Question: How does MDB make money when taking a venture public? - MDB earns equity through pre-IPO financing and charges cash fees, often receiving a blend of cash and equity [65][66] Question: Can you share how much of MDB's value is due to its share of ownership of the companies you've taken public? - The value is significantly tied to the performance of companies like Exozymes and HeartBeam, with potential for substantial impact on MDB's stock price [77][79] Question: Do you ever consider acquisition of companies instead of IPOs? - Currently, the focus is on public venture, but acquisitions could be considered if they align with the company's strategy [81] Question: How many firms do you see out there that are doing what MDB Capital is doing currently? - Management believes there are very few firms that effectively compete with MDB's unique approach to public venture capital [82][84]

Financial Data and Key Metrics Changes - The company reported a modest increase in its shareholder base, onboarding several new accounts interested in the HeartBeam offering [29] - Net current assets decreased by approximately $2.3 million, with less than $2 million in cash utilized during the quarter [35] Business Line Data and Key Metrics Changes - The company is pivoting towards companies that are closer to product revenue and value creation, indicating a shift in focus from deep tech ideas to more profitable ventures [19][48] - The company has three letters of intent (LOIs) with new companies, including a biotech firm with a pre-money valuation of $20 million, a profitable beverage company, and a healthcare software company [20][22][23] Market Data and Key Metrics Changes - The current venture market is characterized by a significant number of companies that have received funding but have not gone public, creating opportunities for the company to take these firms public [11][12] - The company noted a backlog of IPO opportunities due to changing market dynamics, with investors preferring companies that are capital light and closer to profitability [15][17] Company Strategy and Development Direction - The company aims to scale its operations by bringing three to four new investment opportunities to the public market each year, focusing on companies that can resonate in the changing marketplace [43][44] - The management emphasized the importance of valuation and the need to find extraordinary businesses at the right values to provide great return opportunities for investors [20][50] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the small IPO market, suggesting it will be robust and may reverse long-standing downtrends [17] - The management acknowledged the current challenging environment for small companies but remains confident in the company's ability to curate and take public viable businesses [24][49] Other Important Information - The company has restructured its executive compensation plan to align better with shareholder interests, converting a significant amount of stock compensation to options [31][32] - PatentVest is seen as a critical component for value creation, assisting in business development and strategy for the companies it works with [66][70] Q&A Session Summary Question: Can you talk about the company financing the $20 million for the potential cure for diabetes? - The company financing this is PaulX Bio [52] Question: How does management interpret the persistent discount of the MDBH stock price relative to the IPO price? - Management believes it is primarily a supply and demand issue, noting that market perceptions can change over time [54][56] Question: What is the future dividend policy? - The dividend policy will depend on the impact of share distribution on the companies involved and the company's cash flows [58][60] Question: How does the company make money when taking a venture public? - The company earns equity through pre-IPO financing and charges cash fees, often receiving a blend of cash and equity [62][63] Question: How much of MDB's value is due to its share of ownership of the companies taken public? - The company believes that if it had gone public at a better time, its valuation would be significantly higher [74][76] Question: Does the company consider acquisitions instead of IPOs? - Currently, the focus is on public ventures, but the company would consider acquisitions if they are accretive to its public venture strategy [79] Question: How many firms are doing what MDB Capital is doing currently? - Management believes there are very few firms left that can effectively take small companies public, highlighting the company's unique position [81][82]

Financial Data and Key Metrics Changes - The company is unable to provide detailed financial results due to the deconsolidation of Invizyne's financial statements, which has delayed the filing of the 10-K report [6][14][25] - As of December 31, the combination of cash and securities was $28 million, and Big Idea investments, represented by eXoZymes, was $64 million, totaling approximately $93 million [58] - The stock price as of December 31 was $6.30, with approximately 9.9 million shares outstanding, resulting in a market value of $62 million, indicating a negative market value of $30 million [58][59] Business Line Data and Key Metrics Changes - The company has successfully launched eXoZymes, marking a significant achievement despite challenging market conditions for small IPOs [14][15] - The shareholder count has increased by 12%, reaching approximately 1,800 shareholders [15] - The onboarding of investors through MDB Direct has begun, with over 500 accounts established by the end of the year [16] Market Data and Key Metrics Changes - There is a growing demand for microcap financing, with investors seeking liquid alternatives, positioning the company as a top curator of public venture opportunities [32] - The traditional venture capital and private equity markets are facing challenges, leading to increased interest from companies looking to go public [30][31] Company Strategy and Development Direction - The primary strategic priority is to expand the investor community, focusing on partnerships with RIAs and angel groups [35][41] - The company aims to transition from episodic deal-making to creating a consistent public venture asset class portfolio [34] - The company is optimistic about presenting new Big Idea investment opportunities in the near future, with a focus on companies that are more developed and potentially have revenue [80] Management's Comments on Operating Environment and Future Outlook - Management is excited about the significant increase in opportunities being presented, both from community members and through their own curation efforts [26][27] - The regulatory environment is perceived as improving, which may facilitate new offerings, although there are concerns regarding the FDA's approval timelines [87][88] - The company is focused on maintaining operational efficiencies and reducing cash operational expenses while increasing revenue from various lines [62] Other Important Information - The company has licensed new assets from Mayo Clinic and is developing that opportunity, with plans for potential further investment [49][50] - The company continues to work with HeartBeam, which is developing groundbreaking technology for self-administered ECGs, with significant market potential [44] Q&A Session Summary Question: Does Lou Basenese still work for the organization? - Lou Basenese has left the company but remains a friend and supporter, focusing on his media presence [65][66] Question: What does the deconsolidation mean for MDB stockholders and eXoZymes' investors? - The deconsolidation will clarify the financials of MDB, separating its performance from eXoZymes, making it easier to understand [70][71] Question: How many Big Idea companies are expected to be established in 2025? - The company anticipates presenting three to four new Big Ideas this year, with some being more developed and potentially having revenue [80][81] Question: How do you see the regulatory winds changing? - The regulatory environment is perceived as improving, which may facilitate new offerings, although there are concerns regarding the FDA's approval timelines [87][88] Question: When do you expect to make any type of dividend? - The company aims to see a value-creating event within eXoZymes before considering any distributions to shareholders [92][93] Question: How should shareholders think about the investment in cash and resources relative to value creation? - The company intends to maintain a modest amount of cash for new opportunities while leveraging existing investments to create value [99][100]

Financial Data and Key Metrics Changes - The company is unable to provide detailed financial results due to the deconsolidation of Invizyne's financial statements, which has delayed the filing of the 10-K report [6][14][25] - As of December 31, the combination of cash and securities was $28 million, with Big Idea investments represented by eXoZymes valued at $64 million, totaling approximately $93 million in cash and securities [58] - The stock price as of December 31 was $6.30, with approximately 9.9 million shares outstanding, resulting in a market value of $62 million, indicating a negative market value of $30 million [58][59] Business Line Data and Key Metrics Changes - The company has successfully launched eXoZymes, marking a significant achievement despite challenging market conditions for small IPOs [14][15] - The shareholder count has increased by 12%, reaching approximately 1,800 shareholders [15] - The onboarding of investors through MDB Direct has begun, with over 500 accounts established by year-end [16] Market Data and Key Metrics Changes - There is a growing demand for microcap financing, with investors seeking liquid alternatives, positioning the company as a top curator of public venture opportunities [32] - The traditional venture capital and private equity markets are facing challenges, leading to increased interest from companies looking to go public [30][31] Company Strategy and Development Direction - The primary strategic priority for the company is to expand its investor community, focusing on partnerships with RIAs and angel groups [35][41] - The company aims to present one to two new Big Idea investment opportunities in the next quarter, indicating a robust pipeline of potential investments [52][53] - The company is evolving from a model of episodic deal-making to creating a consistent public venture asset class portfolio [34] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the increasing number of opportunities being presented, both from community members and through proactive curation [26][27] - The regulatory environment is perceived as improving, which may facilitate new offerings, although there are concerns regarding the FDA's approval timelines [87][88] - The company is focused on maintaining operational efficiencies while managing cash expenditures, with hopes of reducing operational costs over the next 12 months [62] Other Important Information - The company has licensed new assets from Mayo Clinic and is developing this opportunity, although no specific updates were provided [49][50] - The company continues to work with HeartBeam, which is developing groundbreaking technology for self-administered ECGs, with significant market potential [44] Q&A Session Summary Question: Does Lou Basenese still work for the organization? - Lou Basenese has left the company but remains a friend and supporter, focusing on his media presence [65][66] Question: What does the deconsolidation mean for MDB stockholders and eXoZymes' investors? - The deconsolidation will clarify the financials of MDB, separating its performance from eXoZymes, making it easier for investors to understand [70][71] Question: How many Big Idea companies are expected to be established in 2025? - The company anticipates presenting three to four new Big Ideas in 2025, with some companies already in advanced discussions for potential IPOs [80][81] Question: How do you see the regulatory winds changing? - The regulatory environment is expected to improve, facilitating new offerings, although there are uncertainties regarding FDA timelines [87][88] Question: When do you expect to make any type of dividend? - The company aims to wait for a solid footing under eXoZymes before considering any distributions to avoid disrupting the market [92][93] Question: How should shareholders think about the investment in cash and resources relative to value creation? - The company intends to maintain a modest amount of cash for new opportunities while leveraging existing investments to create value [99][100]